

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

CLAIMS

1-10 Canceled

11. (New) A pharmaceutical composition comprising a therapeutically effective amount of an Active Pharmaceutical Ingredient, a β -cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein said preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.

12. (New) A pharmaceutical composition according to claim 1 wherein the Active Pharmaceutical Ingredient is a compound of Formula I,



I

or its pharmaceutically acceptable salts, wherein R² is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl.

13. (New) The pharmaceutical composition according to Claim 12 wherein the β -cyclodextrin is 2-hydroxypropyl- β -cyclodextrin or sulfobutyl ether- β -cyclodextrin.

14. (New) The pharmaceutical composition according to claim 12 wherein the preservative is selected from thimerosal, propylene glycol, phenol, or meta-cresol or a combination thereof.

15. (New) The pharmaceutical composition according to claim 14 wherein the preservative is about 2.5 mg/ml of meta-cresol.

16. (New) The pharmaceutical composition according to claim 14 wherein the preservative has a binding value to the cyclodextrin that is less than a binding value of the Active Pharmaceutical Ingredient to cyclodextrin.

17. (New) The pharmaceutical composition according to claim 15 wherein about 1 mg/mL to about 5 mg/mL of the preservative is unsequestered in the cyclodextrin.

18. (New) The pharmaceutical composition according to claim 16 wherein the binding value of the Active Pharmaceutical Ingredient to cyclodextrin is between 500 M^{-1} and $10,000 \text{ M}^{-1}$.

19. (New) The pharmaceutical composition according to claim 16 wherein the binding value of the Active Pharmaceutical Ingredient to cyclodextrin is between 800 M^{-1} and $31,000 \text{ M}^{-1}$.

20. (New) The pharmaceutical composition according to claim 12 for use as a medicament.

21. (New) The use of a composition according to any of Claim 12 in the manufacture of a medicament for the treatment of a disease for which a neurokinin receptor antagonist is indicated.

22. (New) A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 12.

23. (New) A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 13.

24. (New) A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 14.

25. (New) A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 15.

26. (New) A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 16.

27. (New) A method for the treatment of a disease for which a neurokinin receptor antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 17.